Group items matching

in title, tags, annotations or url

1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) the differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor.

 Impact: Applications should articulate both the short- and long-term impact of the proposed research. Projects must address one or more of the FY18 SCIRP IIRA Focus Areas.  Military Relevance: Projects should be relevant to spinal cord-injured military Service members, Veterans, and/or their family members and caregivers. Collaboration with military and VA researchers and clinicians is encouraged.  Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the SCIRP and the proposed research project. IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as correlative studies associated with an existing clinical trial.

The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and pursue high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and to transform these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts that address one or more of the following technical domains:

This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community.

It is estimated that more than 30 million Americans over the age of 12 years have hearing loss in both ears and an estimated 48 million have hearing loss in at least one ear. The most recent data from the Department of Veterans Affairs (VA) indicates that there are 1.1 million Veterans with Service-connected disability due to hearing loss. The HRRP will fund innovative research that has the potential to maximize operational performance, medical readiness, and quality of life for Service members, Veterans, and others living with significant auditory system injuries.

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

The NINDS, with other NIH Institutes and Centers participating in the BRAIN Initiative, intends to publish "BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00)." The program is designed to increase biomedical research workforce diversity and foster a strong cohort of new, highly skilled and well trained, NIH-supported, independent investigators from underrepresented groups working in research areas supported by the BRAIN Initiative, as highlighted in BRAIN 2025: A Scientific Vision. It is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This Notice is being provided to allow potential applicants sufficient time to develop meaningful mentoring teams and responsive projects. The FOA is expected to be published in April 2018 with an expected application due date in June 2018. This FOA will utilize the K99/R00 funding activity. Details of the planned FOA are provided below. Research Initiative Details The BRAIN Initiative K99/R00 award is intended for women and members of underrepresented groups who are working in research areas supported by the BRAIN Initiative, who have no more than five years of postdoctoral research experience, and who require at least 12 months of mentored research training and career development (K99 phase) before transitioning to the independent research (R00) phase of the program.

Reissue of RFA-NS-15-009. This Funding Opportunity Announcement (FOA) invites applications to support the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.

This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimers Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.

The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models.

This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.

The Michael J. Fox Foundation has issued a request for proposals to investigate environmental factors that increase Risk for Parkinson's disease. While some evidence links environmental factors with increased risk of PD, according to the foundation much remains unknown regarding the specific environmental risks, their role in disease, and the quantification of their contributions. A better understanding of environmental risk factors for PD could lead to efforts to reduce or prevent such exposures.

Each ACT Fellowship will provide up to $220,000 for up to thirty-three months in support of a systematic and sustained course of study in an empirical science such as physics, psychology, biology, genetics, cognitive science, neuroscience, or sociology. Acceptable courses of study might include a plan to audit undergraduate and graduate-level courses, a plan to spend time in residence at a research lab, or a plan to earn a degree in an empirical science. This iteration of the program also will permit applicants to request that up to one year of the ACT Fellowship be used to support a small-scale pilot scientific research project that improves or enhances the capacity, skill, and talent of the fellow to investigate the above-described Big Questions. Fellows may undertake their study at their home institution or another institution. All fellows must have a faculty mentor in their cross-training discipline.

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke (NINDS) in conjunction with the NIH Pain Consortium. It solicits R21 grant applications from institutions/organizations to perform innovative research that will elucidate the mechanisms underlying migraine, expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and explore new therapeutic targets and therapies for acute migraine management and longer term prevention. 

The purpose of this Funding Opportunity Announcement (FOA) is to support an ancillary study grant application(s) to add psychological, behavioral, and/or neurocognitive assessments to the data collection in adults (> 18 years of age) enrolled at the clinical sites in the Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC) supported by the NIH Common Fund. This ancillary study FOA complements the parent MoTrPAC study by supporting research to elucidate the individual level psychological, behavioral, and neurocognitive characteristics that explain variation in individual response and adherence to a program of physical activity. The ultimate goal of the research supported by this FOA is to characterize individual differences in response to exercise over the course of the MoTrPAC protocol in order to identify novel treatment targets and inform personalized physical activity intervention approaches in the future.

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R01 applications. ALSO listed (R21)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."